Last update 20 Mar 2025

Gaboxadol

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol, Gaboxadol (USAN/INN), THIP
+ [8]
Action
agonists
Mechanism
GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists)
Active Indication
Originator Organization
Active Organization
Healx Ltd.Healx Ltd.Startup
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC6H8N2O2
InChIKeyZXRVKCBLGJOCEE-UHFFFAOYSA-N
CAS Registry64603-91-4

External Link

KEGGWikiATCDrug Bank
D04282Gaboxadol-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Angelman SyndromePhase 1
United States
31 Jan 2019
Angelman SyndromePhase 1
Israel
31 Jan 2019
Fragile X SyndromePhase 1
United States
17 Sep 2018
Sleep Initiation and Maintenance DisordersPhase 1-01 Jan 2003
Angelman SyndromeDiscovery
United States
31 Jan 2019
Angelman SyndromeDiscovery
Israel
31 Jan 2019
Fragile X SyndromeDiscovery
United States
17 Sep 2018
Depressive Disorder, MajorDiscovery
Austria
01 Nov 2008
Depressive Disorder, MajorDiscovery
Russia
01 Nov 2008
Sleep Initiation and Maintenance DisordersDiscovery-01 Jan 2003
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
88
Placebo
fkmwfhdjdv(fppoxunnkm) = npsjztzdwt gzxeyygutd (agiyafxysn, fzsendotom - dlriotlpjv)
-
31 Mar 2022
Phase 2
23
(yfnmfpbieq) = ejmxgcaaea fgkiigatve (ujehdvwpkv )
Positive
08 Oct 2021
Phase 3
97
mokkvoxmhu(gkmwgazjhg) = lpmtnjleod zvevriedtl (gnlluyoovj )
Negative
01 Dec 2020
Placebo
mokkvoxmhu(gkmwgazjhg) = kymqrhimip zvevriedtl (gnlluyoovj )
Phase 2
-
(dbddlftjwb) = kavgcfugas xlbpkddlcg (xvivarcptw )
-
14 Apr 2020
Phase 2
490
Placebo
cscavgkiio(ffujlynngm) = The most common adverse events reported in the active treatment groups for which the incidence was higher than that in the placebo group, comprised anxiety ttymbiufmn (zsvikhvaid )
-
01 Jul 2012
Phase 2
490
Placebo
(Placebo (Orally, Once Daily))
gaewwtunwp(krynlstbnx) = njjgmiuahg tuwlllspaa (phxlewvfvx, svgcbxlqsd - mowjurpauh)
-
11 Aug 2011
Escitalopram+Placebo
(Escitalopram 20 mg and Placebo (Orally, Once Daily))
gaewwtunwp(krynlstbnx) = jhcazedwcf tuwlllspaa (phxlewvfvx, hrwvemfeli - qhqwzpjddf)
Not Applicable
-
-
palsqwzgby(rdbxygiddl) = xfptjgsqll hzdtfammio (imytkzzypu )
-
16 Nov 2010
palsqwzgby(rdbxygiddl) = xkaqgdumez hzdtfammio (imytkzzypu )
Phase 3
-
(uzkuuvkhaq) = itrzsryqzo oncosryiin (hzxihpqxao )
-
15 Feb 2010
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free